Leen Jm Heyens,Demi P A van Malde,Gediz Dogay Us et al.
Leen Jm Heyens et al.
Introduction and objectives: The screening accuracy of non-invasive fibrosis tests like FIB-4 in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Using standard cut-offs, this study evalua...
Telemedicine and hybrid engagement models facilitate hepatitis C cascade of care during periods of healthcare disruption [0.03%]
远程医疗和混合参与模式在医疗卫生中断期间可促进丙型肝炎医疗服务链顺利进行
Sabrina Fan,Haris Imsirovic,Curtis Cooper
Sabrina Fan
Introduction and objectives: To assess the utility of telemedicine on provision of hepatitis C care, we compared characteristics and outcomes of HCV-infected patients engaging in standard in-clinic care, telemedicine only...
Similar hepatic outcome by SGLT2i vs. DPP4i for at-risk cohort with CHB & T2DM: a nationwide target trial emulation study [0.03%]
对于伴有乙型肝炎和2型糖尿病高危人群SGLT2i与DPP4i具有相似的肝脏结局：一项全国性目标试验模拟研究
Byungyoon Yun,Juyeon Oh,Heejoo Park et al.
Byungyoon Yun et al.
Introduction and objectives: The prevalence of diabetes is rising among patients with chronic hepatitis B (CHB). However, the comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus dipeptidyl pe...
Genetic risk factors for MASLD/MASH and cardiovascular disease in elderly individuals [0.03%]
老年人遗传性慢加素肾病和心血管疾病危险因素研究
Willy B Theel,Vivian D de Jong,Diederick E Grobbee et al.
Willy B Theel et al.
Introduction and objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, MASH, are closely related to obesity and lifestyle. From previous studies, MASLD is also known for it...
New molecules for treating Metabolic-associated dysfunction steatotic liver disease (MASLD) [0.03%]
治疗代谢相关脂肪性肝病(MASLD)的新分子
Manuel Romero-Gómez
Manuel Romero-Gómez
Natural history and outcomes of MASLD and MetALD following non-alcoholic fatty liver disease reclassification in a Canadian cohort [0.03%]
加拿大队列中重新界定非酒精性脂肪性肝病后的MASLD和MetALD的自然史及转归
Yousef Almahanna,Francisco Idalsoaga,Luis Antonio Díaz et al.
Yousef Almahanna et al.
Introduction and objectives: Steatotic liver disease (SLD) affects 40% of North Americans, with some progressing to advanced fibrosis. A recent nomenclature update redefined subtypes, distinguishing Metabolic dysfunction-...
Pancreatic involvement and its prognostic impact in acute-on-chronic liver failure [0.03%]
急性-on-慢性肝功能衰竭中胰腺受累及其预后价值
Georg Kramer,Vlad Taru,Benedikt Simbrunner et al.
Georg Kramer et al.
Introduction and objectives: Acute-on-chronic liver failure (ACLF) in cirrhotic patients is marked by a multiorgan failure and high mortality. The role of the pancreas in ACLF is poorly understood. This study evaluated th...
Early-life exposure to tobacco smoke and chronic liver disease incidence in adulthood [0.03%]
生命早期接触烟草烟雾与成人后慢性肝病发病率的关系研究
Xiaoqin Xu,Jiang Li,Yanqi Fu et al.
Xiaoqin Xu et al.
Introduction and objectives: Tobacco exposure during critical developmental windows may have lasting health effects, but its role in the development of chronic liver disease (CLD) remains unclear. This study aimed to exam...
Alarming increase of acute liver failure during Sudan's conflict: a call for urgent global hepatology response [0.03%]
苏丹冲突期间急性肝功能衰竭病例急剧增加：全球肝病学界紧急响应呼吁
Mumen Abdalazim Dafallah,Manasik Mamoun
Mumen Abdalazim Dafallah
Toward standardization and translation of stem cell therapy in liver failure [0.03%]
肝衰竭干细胞治疗的规范化和转化
Parth Aphale,Himanshu Shekhar,Shashank Dokania
Parth Aphale